Aars - alanyl-tRNA synthetase Gene

Also Known as sti; Aars1

Species: Mus musculus

Gene Type: protein coding
Gene ID: 234734

Summary

Enables Ser-tRNA(Ala) hydrolase activity; alanine-tRNA Ligase activity; and translation regulator activity. Involved in alanyl-tRNA aminoacylation; regulation of cytoplasmic translational fidelity; and tRNA modification. Acts upstream of or within cerebellar Purkinje cell layer development; negative regulation of neuron apoptotic process; and neuromuscular process controlling balance. Predicted to be located in cytoplasm. Predicted to be active in mitochondrion. Is expressed in several structures, including adrenal gland; alimentary system; nervous system; respiratory system; and urinary system. Human ortholog(s) of this gene implicated in Charcot-Marie-Tooth disease axonal type 2N and developmental and epileptic encephalopathy 29. Orthologous to human AARS1 (alanyl-tRNA synthetase 1). [provided by Alliance of Genome Resources, Apr 2022]

Aars Products (2)

mRNA Protein Name
NM_146217.4 NP_666329.2 alanine--tRNA ligase, cytoplasmic
NM_146217.4 NP_666329.2 alanine--tRNA ligase, cytoplasmic

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence References Source
enables Ser-tRNA(Ala) hydrolase activity IDA
IDA: Inferred from direct assay
25422440 MGI
enables Ser-tRNA(Ala) hydrolase activity IMP
IMP: Inferred from mutant phenotype
16906134 MGI
enables alanine-tRNA ligase activity IDA
IDA: Inferred from direct assay
27622773 MGI
enables aminoacyl-tRNA editing activity IDA
IDA: Inferred from direct assay
20010690 MGI
enables protein binding IPI
IPI: Inferred from physical interaction
23055941 MGI
Biological Process GO Annotation Evidence References Source
involved in alanyl-tRNA aminoacylation IDA
IDA: Inferred from direct assay
27622773 MGI
acts upstream of or within alanyl-tRNA aminoacylation IMP
IMP: Inferred from mutant phenotype
16906134 MGI
acts upstream of or within cerebellar Purkinje cell layer development IMP
IMP: Inferred from mutant phenotype
16906134 MGI
acts upstream of or within negative regulation of neuron apoptotic process IMP
IMP: Inferred from mutant phenotype
16906134 MGI
acts upstream of or within neuromuscular process IMP
IMP: Inferred from mutant phenotype
16906134 MGI
acts upstream of or within neuromuscular process controlling balance IMP
IMP: Inferred from mutant phenotype
16906134 MGI
acts upstream of neuron apoptotic process IMP
IMP: Inferred from mutant phenotype
16906134 MGI
involved in regulation of cytoplasmic translational fidelity IMP
IMP: Inferred from mutant phenotype
25422440 MGI
involved in tRNA modification IDA
IDA: Inferred from direct assay
25422440 MGI
acts upstream of or within tRNA modification IMP
IMP: Inferred from mutant phenotype
16906134 MGI
involved in tRNA modification IMP
IMP: Inferred from mutant phenotype
29769718 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

alanine--tRNA ligase, cytoplasmic

  • alaRS

  • alanyl-tRNA synthetase, cytoplasmic

  • protein sticky

Recombinant Aars Proteins

Cat. No. Product Name Accession Purity
HY-P75567 AARS1 Protein, Mouse (sf9, His) Q8BGQ7 (M1-N968) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-10122 Silodosin Antagonist 99.89% Yes
HY-B0484 Buflomedil hydrochloride Antagonist 99.86% Unkown
HY-B0484A Buflomedil Antagonist / Unkown

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-107046 UK-432097 Agonist 98.9% Phase 2

Pre-clinical Phase

Bioactive Molecules (43)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-112861 Gln-AMS Inhibitor 99.66% Unkown
HY-100554 BMY 7378 99.92% Unkown
HY-112861A Gln-AMS TFA Inhibitor 99.85% Unkown
HY-101300 Cirazoline hydrochloride Agonist 99.56% Unkown
HY-108939 Aminoacyl tRNA synthetase-IN-1 Inhibitor 99.80% Unkown
HY-D1606 BODIPY FL prazosin Inhibitor 99.71% Unkown
HY-147907 Adenosine receptor inhibitor 1 Inhibitor 98.29% Unkown
HY-RS00028 AARS1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-147908 Adenosine receptor inhibitor 2 Inhibitor 99.08% Unkown
HY-RS00029 AARS2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-103203 ST91 Agonist 99.75% Unkown
HY-147100 α1A-AR Degrader 9c Inhibitor 99.60% Unkown
HY-120826 A2AAR/hMAO-B-IN-1 Inhibitor 99.0% Unkown
HY-162620 α2A-AR agonist 1 Agonist 99.92% Unkown
HY-N12422 A2AAR antagonist 2 Antagonist 99.40% Unkown
HY-RS17458 Aars1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-101514 β3-AR agonist 1 Agonist / Unkown
HY-103203A ST91 free base Agonist / Unkown
HY-116982 BMY 7378 free base / Unkown
HY-143324 A2AAR/HDAC-IN-1 Inhibitor / Unkown
HY-143325 A2AAR/HDAC-IN-2 Inhibitor / Unkown
HY-145480 Silodosin Glucuronide sodium / Unkown
HY-146979 hA2A/hCA XII modulator 1 / Unkown
HY-147643 Aminoacyl tRNA synthetase-IN-2 Inhibitor / Unkown
HY-151139 LJ-4517 Antagonist / Unkown
HY-163701 hA2AAR antagonist 1 Antagonist / Unkown
HY-165509 DU172 Ligand / Unkown
HY-167905 ATL444 Antagonist / Unkown
HY-174413 A2AAR antagonist 3 Antagonist / Unkown
HY-175195 Adenosine receptor antagonist 6 / Unkown
HY-175487 A2AAR antagonist 4 Antagonist / Unkown
HY-175851 A2AAR antagonist 5 Antagonist / Unkown
HY-179605 AR ligand-49 Ligand / Unkown
HY-179681 A2A/A3 agonist-1 Agonist / Unkown
HY-185003 α1A-AR ligand-1 Ligand / Unkown
HY-RS00026 AAR2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-10122A (Rac)-Silodosin Inhibitor / Unkown
HY-10122S Silodosin-d4 Antagonist / Unkown
HY-151387 A2AAR antagonist 1 Antagonist / Unkown
HY-183004 NCP26 / Unkown
HY-RS21465 Aars2 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23915 Aars1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS27983 Aars2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown